Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17926499 | 0.77 | SRC (0.43) | SRCCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL12019998 | 0.69 | CYP1A2 (0.36) | CYP1A2 | |
| SCHEMBL29319840 | 0.67 | SRC (0.53) | SRCCMA1AHR | |
| SCHEMBL13244248 | 0.66 | CYP1A2 (0.37) | CYP1A2 | |
| SCHEMBL260293 | 0.65 | TNNI3K (0.39) | SRCCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2821501 | 0.64 | — | — | |
| SCHEMBL13424558 | 0.62 | MEN1 (0.42) | SRCMEN1MAPTKMT2A | |
| SCHEMBL2453854 | 0.62 | SRC (0.56) | SRCCMA1AHR | |
| SCHEMBL2115445 | 0.62 | CYP1A2 (0.68) | CYP1A2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL275910 | 0.60 | CYP1A2 (0.48) | CYP1A2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338422-B2 | Indolin-2-ones and aza-indolin-2-ones | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8338422-B2 | Indolin-2-ones and aza-indolin-2-ones | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-25 | — | — | US | disclosed |
| US-20100190786-A1 | INDOLIN-2-ONES AND AZA-INDOLIN-2-ONES | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190786-A1 | INDOLIN-2-ONES AND AZA-INDOLIN-2-ONES | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190786-A1 | INDOLIN-2-ONES AND AZA-INDOLIN-2-ONES | IDO2, IDO1, MKI67 | SRC 1560/4885CYP1A2 1065/4885MEN1 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.